Highlights BerGenBio ASA

Equities

BGBIO

NO0010650013

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-15 am EDT			5-day change	1st Jan Change
0.125 ^NOK	0.00%		-8.76%	-55.04%

Mar. 20	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
Feb. 14	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	Mar. 20	CI
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections	Feb. 07	CI
BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients	Dec. 15	CI
BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting	Dec. 11	CI
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Bergenbio Announces Data from Biomarker Analyses in 2L Nsclc	Nov. 06	CI
BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer	23-10-23	CI
BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-22	CI
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO	23-06-05	CI
BerGenBio ASA Presents Data on STK11 Loss of Function and AXL Activation at AACR	23-04-18	CI
BerGenBio ASA Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With Stk11 Mutations	23-03-09	CI
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	23-02-15	CI
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15	CI
BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	22-10-11	CI
BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients	22-09-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BerGenBio ASA

Equities

BGBIO

NO0010650013

Highlights

Filters